BIOMAT Database Logo BIOMAT Database Logo

The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. 1994

E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Merck Research Laboratories, West Point, Pennsylvania.

The nonnucleoside reverse transcriptase (RT) inhibitors are structurally diverse compounds that are specific inhibitors of the human immunodeficiency virus type 1 RT enzyme. The compounds are largely functionally identical and bind to a common site in the enzyme. HIV-1 variants that exhibit reduced susceptibility to these inhibitors have been derived in cell culture and, more recently, from HIV-1-infected patients undergoing experimental therapy. The variants express amino acid substitutions at RT positions that apparently interact directly with the inhibitors. Effects of specific substitutions at these positions vary among the compounds, suggesting subtle differences in how the compounds physically interact with the enzyme.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D001583 Benzoxazoles Benzoxazole
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase

Related Publications

E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.
January 2000, AIDS reviews,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
September 1992, The Journal of biological chemistry,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
November 2013, Antimicrobial agents and chemotherapy,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.
January 2004, Sexual health,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.
July 2014, Viruses,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
November 2006, PLoS pathogens,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
October 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
E A Emini, and V W Byrnes, and J H Condra, and W A Schleif, and V V Sardana
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
January 2006, Current pharmaceutical design,
Copied contents to your clipboard!